Revance Therapeutics, Inc. (NASDAQ:RVNC) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET
Company Participants
Jessica Serra - Head, IR & ESG
Mark Foley - CEO & Director
Dustin Sjuts - President
Tobin Schilke - CFO & Principal Accounting Officer
Conference Call Participants
Seamus Fernandez - Guggenheim Securities
David Amsellem - Piper Sandler & Co.
Chris Shibutani - Goldman Sachs Group
Stacy Ku - TD Cowen
Timothy Lugo - William Blair & Company
Balaji Prasad - Barclays Bank
Annabel Samimy - Stifel, Nicolaus & Company
Navann Dietschi - BNP Paribas Exane
Douglas Tsao - H.C. Wainwright & Co.
Terence Flynn - Morgan Stanley
Charles Uy - Mizuho
Operator
Welcome to the Revance Therapeutics Second Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions]. As a reminder, this call is being recorded today, Tuesday, August 8, 2023. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations, Communications and ESG for Revance. Please go ahead.
Jessica Serra
Thank you, operator. Joining us on the call today with Revance, our Chief Executive Officer, Mark Foley; President, Dustin Sjuts ; and Chief Financial Officer, Toby Schilke. During this conference call, management will make forward-looking statements, including statements related to 2023 guidance, cash flow breakeven, operating leverage, blockbuster potential and capital structure, our ability to draw on our debt, future revenue and expenses, the market, our growth potential, our CD approval and entry into therapeutics, our commercial success, account penetration, injector and consumer preferences and behavior, the efficacy and duration of DAXXIFY, the benefits to us, practices and consumers of our products and strategy, the impact of our marketing and training plans, our strategic partnerships and our strategy and priorities, planned operations and commercialization plans and timing.
Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause results to be different from these statements include factors the company described in the section titled Risk Factors in our annual report on Form 10-K filed with the SEC on February 28, 2023, and our quarterly reports on Form 10-Q filed with the SEC on May 9, 2023, and today, August 8, 2023. Revance undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations. Also on today's call, we will present both GAAP and non-GAAP financial measures. A reconciliation of non-GAAP to GAAP measures is included in our earnings release.